Ireland blamed Northern Ireland Office for ‘damaging leaks’, records showAustralian PM ready to 'engage' with Musk on social media teen banHigh on past, mixing with present
I think it’s a test of bona fides: where is the argument being applied? If somebody wants to make a case that there’s an overhang of capacity in Chinese heavy industry, it wouldn’t be surprising in light of the gear shift in Chinese growth, which was so heavily based around construction and involved a lot of concrete and steel – basic infrastructure buildout. It’s an argument that reflects the difficulty of locating the current moment in Chinese economic history properly. It’s far too superficially seen as just a cyclical downturn, or something like that. It’s actually a far more fundamental break from a truly unique urbanisation push to a new phase, and so there are going to be some adjustment difficulties. It’s clearly been a long-standing issue, and it’s trailed over the global heavy industrial system for a long time. It is significant that [the overcapacity debate] has come up at this moment, because it provides a kind of justification for industrial policy in the West and that’s also the dimension in which it seems to me quite problematic because it concerns the leading edge [of technology]. The new element of this argument is in green tech, and it’s just very difficult to even understand what we mean by the suggestion of, say, excess capacity in [solar] photovoltaics (PV). You can see it from the point of view of Chinese manufacturers who say this themselves, because it’s really difficult to earn a buck in making PV in China. But there’s no reason the rest of the world should have any dog in that particular fight. That’s industrial firms in China competing as hard as they do and using all of the tools in the book. 02:54 Trump threatens new anti-drug tariffs on ‘day 1’ for China, Canada, MexicoMELBOURNE, Australia and INDIANAPOLIS , Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®[1], 89 Zr- girentuximab) kidney cancer imaging[2]. TLX250-CDx is an investigational PET[3] drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix's successful urology imaging franchise. The FDA is expected to advise the PDUFA[4] goal date following the 60-day administrative review of the application. Kevin Richardson , Chief Executive Officer, Precision Medicine at Telix, stated, "We are pleased to be progressing the BLA for TLX250-CDx, which has been granted Breakthrough designation, and may therefore be eligible for priority review. Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC." About TLX250-CDx TLX250-CDx (Zircaix® 1 ) is an investigational PET agent that is under development for the diagnosis and characterisation of ccRCC. Telix's pivotal Phase III ZIRCON trial (ClinicalTrials.gov ID: NCT03849118 ) evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent radiology readers[5]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterising ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[6], by the Australian Therapeutic Goods Administration (TGA) [7], and by Health Canada [8] . No other Telix product has received a marketing authorisation in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn . Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected] This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States . The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Zircaix® 1 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. [1] Brand name subject to final regulatory approval. [2] Telix ASX disclosure 31 July 2024. The FDA requested additional data demonstrating adequate sterility assurance during dispensing of TLX250-CDx in the radiopharmacy production environment. [3] Positron emission tomography. [4] Prescription Drug User Fee Act. [5] Shuch et al. Lancet Oncol. 2024. Telix ASX disclosures 7 November 2022. [6] Telix ASX disclosure 20 December 2021. [7] Telix ASX disclosure 2 November 2021. [8] Telix ASX disclosure 14 October 2022. SOURCE Telix Pharmaceuticals Limited
Australian PM ready to 'engage' with Musk on social media teen banWelcoming the new year with big financial dreams, the crypto community is abuzz with anticipation. BlockDAG Network has thrown down the gauntlet with its $1M USDT New Year’s Raffle, while Ethereum is eyeing a significant jump to $12,000. Ethereum continues to captivate with its enhancements in scalability and the burgeoning DeFi sector, but BlockDAG is making waves with its unique way of doling out crypto bonuses along with raffle rewards. Thanks to a strong presale showing and solid backing from buyers, BlockDAG offers both immediate gains and promising prospects. With XRP also stirring excitement with its 2025 forecasts, BlockDAG is quickly becoming the go-to for those keen on exploring fresh opportunities in crypto. Kick Off 2025 with a Bang and a Million-Dollar Opportunity Is there a better way to dive into 2025 than joining BlockDAG’s $1M USDT New Year’s Raffle? It’s not just a winning opportunity; it’s a festive celebration of new beginnings, offering a chance to bag up to $1 million USDT. BlockDAG ensures everyone can throw their hat in the ring, with ticket options crafted to suit any budget. The Bronze Ticket allows for an easy entry with just 125 USDT and a potential win of up to $250,000 USDT. Want to up your game? The Silver Ticket at 250 USDT offers a great balance of cost and potential gain. For the high rollers, the Gold Ticket at 500 USDT not only amplifies your odds for the million-dollar jackpot but also sweetens the deal with a 200% boost in BDAG coins. Unlike typical raffles, this one enriches your portfolio with crypto bonuses as you chase the big prize. The choice of ticket tiers makes it welcoming for all, adding an extra thrill with its grand prize. BlockDAG’s significant strides in the crypto market underscore its appeal, with its 26th presale batch raking in $173.5 million and selling over 17.5 billion BDAG coins, marking a 2240% growth from its inception. Ethereum’s Upcoming Surge: A $12,000 Price Target on the Horizon Ethereum is gearing up for an impressive rally, with analysts setting sights on a $12,000 target in the next market cycle. This bullish outlook is driven by continuous tech innovations, particularly the introduction of sharding, which will boost network efficiency and speed by segmenting the blockchain. Layer-2 solutions like Arbitrum and Optimism are also easing congestion and cutting costs, making Ethereum even more appealing. As Ethereum cements its status at the forefront of DeFi and NFTs, it faces hurdles like new competitors and potential regulatory changes that could influence its trajectory. XRP’s 2025 Price Forecast: The Potential Value of 1,000 Tokens The buzz around XRP’s 2025 price forecast is electric, fueled by Ripple’s expanding adoption and stellar market performance. With its current price around $3 and a near fivefold increase last year, experts are optimistic about continued growth, estimating XRP could hit $5–$7 by mid-2025. Such an outcome would significantly increase the worth of 1,000 XRP tokens to between $5,000 and $7,000. However, the unpredictable nature of the crypto market calls for a balanced approach. Factors such as global regulatory changes and Ripple’s strategic decisions will be crucial in shaping XRP’s future. Despite these challenges, XRP’s role in streamlining cross-border payments and potential inclusion in CBDCs enhances its long-term appeal. Summing Up As 2025 looms, the crypto landscape is ripe with thrilling and lucrative opportunities. BlockDAG’s $1M USDT New Year’s Raffle presents a blend of immediate enjoyment and long-term holding potential, making it a bullish crypto which is appealing to all levels of participants. With Ethereum’s technological leaps and XRP’s upbeat price predictions, the diverse trajectories of cryptocurrencies are set to play significant roles in the financial sphere of the future. Moreover, BlockDAG’s blend of successful presale achievements, notable returns, and broad accessibility underlines its increasing importance in the crypto market. Presale: https://purchase.blockdag.network Website: https://blockdag.network Telegram: https://t.me/blockDAGnetworkOfficial Discord: https://discord.gg/Q7BxghMVyu Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp _____________ Disclaimer: Analytics Insight does not provide financial advice or guidance. Also note that the cryptocurrencies mentioned/listed on the website could potentially be scams, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. You are responsible for conducting your own research (DYOR) before making any investments. Read more here.
Edmonton housing coalition hosts wintry rally for more social housing
The Washington Commanders have received both good and bad news regarding their running back situation this week. Brian Robinson, Jr. will play on Sunday against the Tennessee Titans, but Austin Ekeler has been placed on injured reserve . Ekeler, who is dealing with his second concussion of the 2024 season, will be out at least four weeks. That means the earliest he can come back will be in the Commanders' Week 18 regular-season finale in Dallas. Ekeler has appeared in 11 games this season and has racked up 701 total yards from scrimmage, 355 rushing and 346 receiving. He has additionally scored five touchdowns, all on the ground. On the positive side for Washington, Robinson's available status for Sunday following an ankle injury against Dallas last week should keep the Commanders' ground attack moving. Jeremy McNichols and Chris Rodriguez, Jr. should expect to be tasked to step up in Ekeler's absence. Head injuries are nothing to take lightly, so this is the right call to err on the side of caution with Ekeler. All hopes are for a full and quick recovery so that the veteran RB can ideally contribute in the playoffs should the Commanders qualify.Hutson scores 20 as Northern Iowa defeats Southern Illinois 78-67Republican Senator Offers Candid Explanation For Why Matt Gaetz’s Nomination Failed
Mayor Ken Sim says abolition of elected park board will mean $70M in savingsSimon Harris’s Fine Gael party and coalition partner Fianna Fail look set to return to government after the Irish election, but the prime minister could face a battle to keep his post after his popular support appeared to drop. With counting still ongoing, early tallies and the official exit poll showed little to separate the two main incumbent parties and the opposition Sinn Fein. With no party having enough support to govern alone, the status quo will likely remain after Fine Gael and Fianna Fail ruled out a deal with Sinn Fein. Although the overall outcome looks increasingly clear, it’s far from certain Harris will emerge with the upper hand in what could be difficult negotiations with Fianna Fail. Micheal Martin’s party trailed in the official exit poll, but early results suggest it could emerge with the most first-preference votes — the simplest gauge of popular support — putting him in a better position in talks. “It’s far too hard to call at this stage as to who will come out as the largest party,” Harris told RTE on Saturday. “What is clear is that Fine Gael, Fianna Fail and Sinn Fein will be tightly bunched when it comes to final seats.” Martin predicted his Fianna Fail would outperform the exit poll, telling reporters there’s a “route to a very strong finish” for his party. But he cautioned that electoral fragmentation meant forming a government would be “challenging.” To be sure, the picture could change as counting takes in second-choice and subsequent preferences to determine final makeup of the Dail or parliament. A tight race is far from what Harris envisaged when he called the vote early — it wasn’t scheduled to be held until March — to try to capitalize on Fine Gael’s surge in support since he became Taoiseach in April. The media dubbed it the “Harris hop” and the 38-year-old made his campaign slogan “new energy” — despite being a former health minister and established government figure. A giveaway budget and what appeared to be a slump in support for Sinn Fein made it seem the optimal time to seek a new mandate. But Harris’s campaign was beset with slip-ups, starting with Ryanair Holdings Plc Chief Executive Officer Michael O’Leary using a Fine Gael event to make a jibe about teachers serving in government. The worst, though, was a viral video of Harris walking away from a disability care worker and dismissing her view that the government wasn’t doing enough. He later apologized. “Fine Gael may be a little bit disappointed that they didn’t make more gains,” said Lisa Keenan, political science assistant professor at Trinity College Dublin, though she added that given the campaign gaffes, Harris is also likely to be somewhat relieved. “We’ve seen a stabilization there.” From a commanding poll lead as late as September, Fine Gael appears to have slipped back into a three-party scramble to win the popular vote. It’s a key moment. Whoever forms the next government will enjoy a budget surplus and soaring tax receipts from U.S. companies including Apple Inc. operating there. What to do with Ireland’s billions has been a key focus of the election, with parties competing on spending ideas — even as the reelection of Donald Trump in the U.S. and his threat of trade tariffs injected a sense of caution. Worryingly for Harris, the exit poll also showed the premier trailing his two main rivals on the question of who should be next Taoiseach. Only 27% said they want the Fine Gael leader leading the country, while 35% said they would like Fianna Fail’s Martin, and 34% preferred Sinn Fein leader Mary Lou McDonald. McDonald’s strength comes from her support among young people, and that gels with the exit poll showing housing and homelessness were the biggest issues for voters, followed by the cost of living. Data published on election day showed homelessness in Ireland reached a record figure of almost 15,000. Sinn Fein’s steady rise has shaken up Irish politics since McDonald took over from Gerry Adams as president in 2018, becoming its first leader unconnected to the sectarian violence in Northern Ireland known as the Troubles. Its left-leaning agenda appealed to voters struggling with a housing shortage and rising inflation. While its support is well below the start of the year, when Sinn Fein appeared on course to form a government, the exit poll and early counting shows McDonald has established Sinn Fein as an electoral force. That has major implications for Irish politics. Fianna Fail and Fine Gael led every government since the state was formed 100 years ago, and while that looks set to continue, Sinn Fein’s emergence changes the dynamic. Still, without the option of a coalition with Fine Gael or Fianna Fail, Sinn Fein has no clear route to power. That means the focus in the coming days and likely weeks will be on Fine Gael and Fianna Fail and the arrangement they come to. Early tallies suggest Fianna Fail will improve on its performance in 2020, when the party that was in power during the 2008 financial crash reentered government for the first time in almost a decade. It’s possible that it wins several more seats than Fine Gael, which would give it considerable bargaining power in coalition talks and potentially restoring Martin, who served as prime minister for almost two years as part of the job share agreement between Fianna Fail and Fine Gael last time, as Taoiseach. Any deal between Fine Gael and Fianna Fail would not be the end of the story. Even combining their support, the two parties are likely to fall short of the 88 seats needed for a majority in the 174-seat parliament. The third coalition partner last time, the Green Party, face losses — not unusual for minor parties and also reflecting trends for green parties across Europe. Tallies suggest it could lose the majority of its 12 seats. But other smaller parties are expected to make gains. The Social Democrats, whose leader Holly Cairns gave birth on election day, could pick up seats. Labour are also optimistic. Although vote counting began at 9 a.m. on Saturday, a fuller picture is not expected until Sunday. Then the negotiations will begin. ©2024 Bloomberg L.P. Visit bloomberg.com. Distributed by Tribune Content Agency, LLC.Mpaka 4-4 0-0 8, Benjamin 5-11 3-4 15, N.Krass 1-8 0-0 3, Martinez 1-2 0-0 3, Miles 1-6 2-2 4, Harrison 10-18 6-8 27, Mizell 0-0 1-4 1. Totals 22-49 12-18 61. Graham 1-1 0-0 2, Aranguren 6-14 5-8 21, Davis 0-9 5-6 5, Gadsden 2-3 1-2 6, Sanders 2-11 2-2 7, Farmer 1-3 2-2 5, Sunday 1-3 1-1 3, Robinson 2-4 0-0 6, DeCady 1-2 1-1 3, Plotnikov 0-0 1-2 1. Totals 16-50 18-24 59. Halftime_Tarleton St. 31-26. 3-Point Goals_Tarleton St. 5-10 (Benjamin 2-5, N.Krass 1-1, Martinez 1-1, Harrison 1-2, Miles 0-1), Hofstra 9-28 (Aranguren 4-10, Robinson 2-4, Gadsden 1-1, Farmer 1-2, Sanders 1-6, Davis 0-5). Fouled Out_N.Krass, Graham. Rebounds_Tarleton St. 37 (Miles 9), Hofstra 28 (Sunday 7). Assists_Tarleton St. 10 (Martinez 4), Hofstra 11 (Davis 7). Total Fouls_Tarleton St. 18, Hofstra 18. A_362 (4,000).
TALLAHASSEE, Fla. (AP) — Luke Kromenhoek threw for 209 yards and tossed three touchdown passes as Florida State halted a six-game losing streak and routed Charleston Southern 41-7 on Saturday. Kromenhoek completed 13 of 20 passes in his first college start, including a 71-yard touchdown pass to Ja’Khi Douglas, as the Seminoles (2-9) won for the first time since Sept. 21. The true freshman also connected with Amaree Williams for a 4-yard TD and Hykeem Williams for a 10-yard TD. Florida State had the nation’s lowest scoring offense at 13.3 points. The Seminoles hadn’t scored more than 21 points or surpassed the 300-yard mark in 2024. But Florida State overwhelmed FCS Charleston Southern (1-11), accumulating 415 offensive yards. Kaleb Jackson completed 22 of 32 passes for 218 yards, including a 7-yard touchdown pass to Landon Sauers, and an interception for the Buccaneers. The takeaway Charleston Southern: While the Buccaneers found some success through the air, they couldn’t sustain drives and managed just 57 rushing yards on 29 carries. Florida State: The Seminoles picked up a season-best 176 rushing yards, scoring 17 points in the second quarter and 14 points in the third quarter to take control. Up next Charleston Southern’s season is over. Florida State plays host to Florida on Nov. 30. AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football . Sign up for the AP’s college football newsletter: https://apnews.com/cfbtop25